Integ. Capital (539149)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹2.39 provides a small asset floor, with price at 1.66 times book.
• Market cap is tiny at ₹14 Cr, leaving scope for a meaningful recovery if operations revive.
• Current price is near the lower end of the 52-week range (₹3.21 to ₹5.62), reducing some speculative enthusiasm.
• No dividend payout means no cash leakage while the company tries to stabilise.

Concerns

• Latest quarter shows zero revenue and a net loss of ₹1 Cr; sales growth is -78.95%.
• Profit growth of -1350% with negative ROE and ROCE shows capital destruction.
• Piotroski F-Score of 2/9 indicates very weak fundamentals and high bankruptcy risk.
• Promoter holding is not disclosed, and dividend yield is zero; data is insufficient for a confident valuation.

AI Analysis

Looking at Integ. Capital, I see a business that fails the first test Graham taught: is it a business with dependable earnings? The latest quarter shows sales of ₹0 Cr and a net loss of ₹1 Cr. Sales growth has collapsed by 78.95% and profit growth is -1350%. When a consulting services firm cannot generate any revenue, its franchise is worthless regardless of the industry. I don't know what moat exists, but none appears in these numbers. The balance sheet shows book value of ₹2.39 per share, and I'm asked to pay ₹3.96, or 1.66 times book, for a company losing money. That is not a margin of safety; it is a margin of hope. ROE is -1.14% and ROCE is -0.17%, so the small capital base isn't earning anything. With Piotroski F-Score of 2 out of 9, financial health is poor—this score identifies firms with deteriorating fundamentals. There is no dividend to compensate me while waiting. Promoter holding is not disclosed, so I cannot know if insiders are aligned with me. In Buffett's terms, it's far better to buy a wonderful company at a fair price than a poor company at a cheap price; here, the price isn't even particularly cheap at 1.66 times a declining book value. The 52-week range of ₹3.21 to ₹5.62 shows a falling, thinly traded microcap. This is not a compounder. It might be a revival story one day, but I need evidence of new business, revenue, and profitability before I risk a paisa. In the words of Graham, price is what you pay, value is what you get. Here, value is elusive. I'll pass and wait for a better bargain.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer